Percent free prostate-specific antigen: Entering a new era in the detection of prostate cancer

Mayo Clinic Proceedings

Volumn 72, Issue 4, 1997, Pages 337-344

  Vashi, Apoorva R ^a   Oesterling, Joseph E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; CANCER DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; HUMAN; MALE; MALE GENITAL TRACT CANCER; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW;

EID: 0031412419     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/72.4.337     Document Type: Review

References (52)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. ÇA Cancer J Clin 1997; 47:5-27
2. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17:159-163
3. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145:907-923
4. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147:841-845
5. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151:1283-1290
6. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organconfined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993:270:948-954
7. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152:1732-1736
8. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tic) prostate cancer. JAMA 1994; 271:368-374
9. Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, et al. Clinical stage BO or Tic prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology 1993; 41:3-8
10. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317:909-916
11. Monda JM, Barry MJ, Oesterling JE. Prostate specific antigen cannot distinguish stage Tla (Al) prostate cancer from benign prostatic hyperplasia. J Urol 1994; 151:1291-1295
12. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142:1011-1017
13. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141:873-879
14. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147:817-821
15. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD): role in patient evaluation and management. Urol Clin North Am 1993 Nov; 20:653-663
16. Oesterling JE, Chute CG, Jacobsen SJ, Guess HA, Panser LA, Johnson CL, et al. Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men [abstract]. J Urol 1993; 149(Suppl):412A
17. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267:2215-2220
18. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270:860-864
19. Dalkin BL, Ahmann F, Southwick P, Bottaccini MR. Derivation of normal prostate specific antigen (PSA) level by age [abstract]. J Urol 1993; 149(Suppl):413A
20. Collins GN, Lee RJ, McKelvie GB, Rogers AC, Hehir M. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. BrJUrol 1993; 71:445-450
21. Christensson A, Laurell CB, Lilja H. En/ymatic activity of prostatespecific antigen and its reactions with extracellular serine proteinase inhibitors. EurJBiochem 1990; 194:755-763
22. Lilja H, Christensson A, Dahlén U, Matikainen M-T, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with a,-antichymotrypsin. Clin Chem 1991 ; 37:1618-1625
23. Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and cXjantichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51:222-226
24. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen M, Cockett ATK, et al. Serum prostate specific antigen complexed to a 1 -antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150:100-105
25. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostatespecific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274:1214-1220
26. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995; 46:187-194
27. Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change: data from the American Cancer Society National Prostate Cancer Detection Project. Cancer 1994; 74:1615-1620
28. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152:2031-2036
29. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152:1163-1167
30. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996; 47:511-516
31. Richardson TD, Oesterling JE. Age-specific reference ranges for serum PSA. Urol Clin North Am [in press]
32. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, et al. Serum prostate-specific antigen in a communitybased population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995; 75:347-353
33. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med 1996; 335:304-310
34. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152:2037-2042
35. Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, Oesterling JE. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. JUrol 1996; 155:1336-1339
36. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: anew era. Urology 1995; 45:729744
37. Klee GG, Lerner SE, Jacobsen SJ, Bergstralh EJ, Lilja H, Pettersson K, et al. Predictive power of free:total PSA ratio is not superior to total PSA in the diagnosis of prostate cancer in the community setting [abstract]. JUrol 1996; 155(Suppl):371A
38. Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, et al. Détermination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49:19-27
39. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36
40. Catalona WJ, Colberg JW, Smith DS, Ornstein DK, Shayka JJ. Measurement of percent-free PSA improves specificity for lower PSA cutoffs in prostate cancer screening. J Urol 1996; 155(Suppl):422A
41. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. JUrol 1992; 147:846-851
42. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143:747-752
43. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. JUrol 1994; 151:1571-1574
44. Bangma CH, Kranse R, Blijenberg B, Schröder FH. The value of screening tests in the detection of prostate cancer: a simulation of the role of the F/T ratio, age-specific reference ranges, and PSA density. Urology [in press]
45. Miller MI, Katz AE, Ikeguchi E, Olsson CA, Benson MC. Patient outcome when free:total (F:T) PSA, PSA density and PSA velocity are utilized to improve serum PSA specificity: a 5 year study [abstract]. JUrol 1996; 155(Suppl):369A
46. Partin AW, Subong ENP, Kelley CA, Hortopan S, Carter HB, Chan DW, et al. Prospective analysis of free PSA to total PSA ratio (PSA,/ PSAT) for prostate cancer detection & the clearance rate of PSAF after radical prostatectomy [abstract]. JUrol 1996; 155:416A
47. Reissigl A, Klocker H, Pointner J, Ennemoser O, Fink K, Bartsch G. Improvement of prostate cancer (PCA) screening by determination of the ratio free/total (f/t) PSA in addition to PSA levels: a prospective study [abstract]. JUrol 1996; 155(Suppl):370A
48. Yemoto CM, Nolley R, Prestigiacomo AF, Stamey TA. Free (f) and total (t) PSA density in patients with prostate cancer (CaP) and benign prostatic hyperplasia (BPH) [abstract]. J Urol 1996; 155(Suppl):374A
49. Arcangeli CG, Shepherd DL, Smith DS, Humphrey PA, Keetch DW, Catalona WJ. Correlation of percent free PSA with pathologic features of prostatic carcinomas [abstract]. J Urol 1996; 155(Suppl):415A
50. Henricks WH, England BG, Giacherio DA, Oesterling JE, Wojno KJ. Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma [abstract]. J Urol 1996; 155(Suppl): 369A
51. Partin AW, Subong ENP, Jones KA, Marschke PLS, Epstein JI, Chan D W, et al. Free/total PSA does not improve the prediction of final pathological stage for men with localized prostate cancer [abstract]. J Urol 1996; 155(Suppl):415A
52. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. JUrol 1995; 154:1090-1095